

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                                    |   |                                   |
|------------------------------------|---|-----------------------------------|
| In re application of:              | ) | Examiner: Li, Ruixiang            |
|                                    | ) |                                   |
| Sarah C. BODARY, et al.            | ) | Art Unit: 1646                    |
|                                    | ) |                                   |
| Application Serial No. 10/527,469  | ) | Confirmation No. 2209             |
|                                    | ) |                                   |
| Filed: March 6, 2006               | ) | Attorney's Docket No. GNE-0261 R1 |
|                                    | ) |                                   |
| For: <b>NOVEL COMPOSITIONS AND</b> | ) | <b>Customer No. 77845</b>         |
| <b>METHODS FOR THE TREATMENT</b>   | ) |                                   |
| <b>OF IMMUNE RELATED DISEASES</b>  | ) |                                   |

---

**FILED VIA EFS ON JULY 1, 2008**

**RESPONSE TO NON-COMPLIANT RESPONSE TO RESTRICTION REQUIREMENT**

**MAIL STOP — AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The present response is being filed in response to a Notice of Non-compliant mailed June 4, 2008 in response to the Restriction Requirement mailed on March 17, 2008 in connection with the above-identified application. The present response is being timely filed within the one-month shortened statutory time period set for the response.

In the Notice, the Examiner indicates that Applicants' response filed on April 16, 2008 is not responsive because the selected SEQ ID NOS: 147 and 148 do not exist in the instant application. Please note that the Examiner has already pointed out the defect in Applicants Response of April 16, 2008 in a telephone communication with Applicants dated May 22, 2008, where the Examiner suggested that Applicants submit a supplemental response to correct such an error. Applicants submitted on June 10, 2008 a Supplemental Response and Amendment following the Examiner's suggestion. In the Response filed on April 16, 2008, Applicants elected Groups III with traverse, Claims 12, 13, 14-17 (in part), drawn to an antibody which specifically binds to a polypeptide according to claim 10 and composition thereof. Applicants further elected SEQ ID NO:147 (nucleic acid) and 148 (polypeptide) (PRO1265;DNA304827) for further prosecution. Applicants have submitted in the Supplemental Response that, due to a

typographical error, SEQ ID NO:147 in fact should be SEQ ID NO:43 while SEQ ID NO:148 should be SEQ ID NO:44.


As a proof, enclosed please find a copy of the Supplemental Response of June 10, 2008 and a copy of the EFS filing receipt. Applicants respectfully request the Examiner that the amendment and election of the Response of June 10, 2008 be considered by the Examiner.

### **CONCLUSION**

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. **07-1700** (referencing Attorney's Docket No. **GNE-0261 R1**).

Respectfully submitted,

Dated: July 1, 2008

By:   
Panpan Gao (Reg. No. 43,626)

**GOODWIN PROCTER LLP**  
135 Commonwealth Drive  
Menlo Park, California 94025  
Telephone: (650) 752-3100  
Facsimile: (650) 853-1038

**Acknowledgement Receipt**

The USPTO has received your submission at **18:32:49** Eastern Time on **10-JUN-2008**.

No fees have been paid for this submission. Please remember to pay any required fees on time to prevent abandonment of your application.

**eFiled Application Information**

|   |   |
|---|---|
| EFS ID                                    | 3434370   |
| Application Number                        | 10527469  |
| Confirmation Number                       | 2209  |
| Title                                     | Novel compositions and methods for the treatment of immune related diseases |
| First Named Inventor                      | Sarah C Bodary  |
| Customer Number or Correspondence Address | 9157  |
| Filed By                                  | Ginger R. Dreger/C Fong   |
| Attorney Docket Number                    | P1975R1   |
| Filing Date                               | 06-MAR-2006   |
| Receipt Date                              | 10-JUN-2008   |
| Application Type                          | U.S. National Stage under 35 USC 371  |

**Application Details**

| Submitted Files          | Page Count | Document Description                             | File Size         | Warnings        |
|--------------------------|------------|--|-------------------|-----------------|
| scan_20080610_152642.pdf | 6          |  | 191276 bytes      | ◆ PASS          |
|                          |            | <b>Document Description</b>                      | <b>Page Start</b> | <b>Page End</b> |
|                          |            | Miscellaneous Incoming Letter                    | 1                 | 1               |
|                          |            | Response to Election / Restriction Filed         | 2                 | 2               |
|                          |            | Claims   | 3                 | 3               |
|                          |            | Applicant Arguments/Remarks Made in an Amendment | 4                 | 6               |

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

## New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

*If you need help:*

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail [EBC@uspto.gov](mailto:EBC@uspto.gov) for specific questions about Patent e-Filing.*
- *Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#) .*
- *If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.*